EP1028735A4 - Therapeutic methods comprising use of a neuregulin - Google Patents

Therapeutic methods comprising use of a neuregulin

Info

Publication number
EP1028735A4
EP1028735A4 EP98949803A EP98949803A EP1028735A4 EP 1028735 A4 EP1028735 A4 EP 1028735A4 EP 98949803 A EP98949803 A EP 98949803A EP 98949803 A EP98949803 A EP 98949803A EP 1028735 A4 EP1028735 A4 EP 1028735A4
Authority
EP
European Patent Office
Prior art keywords
neuregulin
therapeutic methods
therapeutic
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98949803A
Other languages
German (de)
French (fr)
Other versions
EP1028735A1 (en
Inventor
Robert N Mcburney
William Holt
David I Gwynne
Mark Marchionni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cenes Pharmaceuticals Inc
Original Assignee
Cenes Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cenes Pharmaceuticals Inc filed Critical Cenes Pharmaceuticals Inc
Publication of EP1028735A1 publication Critical patent/EP1028735A1/en
Publication of EP1028735A4 publication Critical patent/EP1028735A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP98949803A 1997-10-14 1998-10-08 Therapeutic methods comprising use of a neuregulin Withdrawn EP1028735A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6210997P 1997-10-14 1997-10-14
US62109P 1997-10-14
PCT/US1998/021349 WO1999018976A1 (en) 1997-10-14 1998-10-08 Therapeutic methods comprising use of a neuregulin

Publications (2)

Publication Number Publication Date
EP1028735A1 EP1028735A1 (en) 2000-08-23
EP1028735A4 true EP1028735A4 (en) 2003-08-06

Family

ID=22040281

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98949803A Withdrawn EP1028735A4 (en) 1997-10-14 1998-10-08 Therapeutic methods comprising use of a neuregulin

Country Status (6)

Country Link
EP (1) EP1028735A4 (en)
JP (1) JP2001519400A (en)
KR (1) KR20010031103A (en)
AU (1) AU745324B2 (en)
CA (1) CA2306228A1 (en)
WO (1) WO1999018976A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
FR2793684B1 (en) * 1999-05-17 2001-08-10 Ethypharm Lab Prod Ethiques USE OF BIODEGRADABLE MICROSPHERES RELEASING ANTI-CANCER AGENT FOR THE TREATMENT OF GLIOBLASTOMA, PROCESS FOR PREPARING SUCH MICROSPHERES AND SUSPENSION CONTAINING THEM
US6825333B1 (en) 1999-08-20 2004-11-30 Chiron Corporation EGFH2 genes and gene products
US7538197B2 (en) * 2000-02-11 2009-05-26 Proteosys Ag Use of neuregulin-β as an indicator and/or target
DE10006175A1 (en) * 2000-02-11 2001-08-23 Andre Schrattenholz Isoform of neuregulin-beta with acidic isoelectric point, useful as indicator or target, e.g. in screening for potential neurological agents
WO2003014156A2 (en) 2001-08-06 2003-02-20 Proteosys Ag NEUREGULIN-β ISOFORMS ASSOCIATED WITH NEURONAL PROCESSES
AU2002304965A1 (en) 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
AU2003237367A1 (en) 2002-06-03 2003-12-19 Chiron Corporation Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
WO2006097463A2 (en) * 2005-03-15 2006-09-21 Ares Trading S.A. Compositions and methods for treating and diagnosing inflammatory disorders
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
RU2457854C2 (en) 2005-12-30 2012-08-10 Цзэньсунь (Шанхай) Сайенс Энд Текнолоджи Лимитед Prolonged release of neuregulin for improvement in cardiac function
CA2705328C (en) 2007-11-16 2018-01-02 Proteosys Ag Active soluble post-translationally modified neuregulin isoforms
EP2276502A4 (en) * 2008-05-23 2012-04-04 Morehouse School Of Medicine Compositions for the prevention and treatment of neuroinjury and methods of use thereof
RU2501564C2 (en) 2008-08-15 2013-12-20 Акорда Терапьютикс, Инк. Compositions and methods for treating non-acute periods following neurological damage
WO2010084150A1 (en) 2009-01-23 2010-07-29 Proteosys Ag Diagnostic method for detecting neurodegenerative diseases
CA2708674C (en) * 2009-05-22 2018-05-15 Morehouse School Of Medicine Compositions comprising neuregulin for the prevention and treatment of neuroinjury and methods of use thereof
KR101186218B1 (en) * 2009-08-21 2012-10-08 경희대학교 산학협력단 Use of EGF-like Domain Peptide of Heregulin Beta 1
US20130143805A1 (en) * 2010-08-13 2013-06-06 Georgetown University Ggf2 and methods of use
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
JP2013135660A (en) * 2011-11-28 2013-07-11 Nara Institute Of Science & Technology Neuregulin-1 partial peptide
PL2830645T3 (en) * 2012-03-30 2018-01-31 Acorda Therapeutics Inc Neuregulin for use in treating peripheral nerve injury
KR20230132635A (en) 2013-05-22 2023-09-15 젠순 (상하이) 사이언스 앤드 테크놀로지 캄파니 리미티드 Extended release of neuregulin for treating heart failure
CN110946993A (en) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 Formula of neuregulin preparation
CN105497876B (en) 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 Methods and compositions for the prevention, treatment or delay of cardiac ventricular arrhythmias with neuregulin
CN111407882A (en) 2014-10-17 2020-07-14 上海泽生科技开发股份有限公司 Methods and compositions of neuregulin for preventing, treating, or delaying heart failure with preserved ejection fraction
CN108778315A (en) * 2016-04-19 2018-11-09 莱布尼茨研究所-针对老化研究(弗里茨利普曼研究所) Nerve modulation element for treating and/or preventing nervous system neoplasm
AR121035A1 (en) 2019-04-01 2022-04-13 Lilly Co Eli NEUREGULIN-4 COMPOUNDS AND METHODS OF USE
KR20220066116A (en) 2019-09-16 2022-05-23 젠순 (상하이) 사이언스 앤드 테크놀로지 캄파니 리미티드 Recombinant human neuregulin derivatives and uses thereof
CN113289002A (en) 2020-02-24 2021-08-24 上海泽生科技开发股份有限公司 Methods and compositions for the prevention, treatment or delay of heart failure using neuregulin

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996015812A1 (en) * 1994-11-17 1996-05-30 Cambridge Neuroscience, Inc. Use of neuregulins as modulators of cellular communication
WO1996030403A1 (en) * 1995-03-27 1996-10-03 Cambridge Neuroscience, Inc. Methods of treating disorders of the eye

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530109A (en) * 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
DE59307910D1 (en) * 1992-03-05 1998-02-12 Ciba Geigy Ag Reactive dyes, processes for their production and their use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996015812A1 (en) * 1994-11-17 1996-05-30 Cambridge Neuroscience, Inc. Use of neuregulins as modulators of cellular communication
WO1996030403A1 (en) * 1995-03-27 1996-10-03 Cambridge Neuroscience, Inc. Methods of treating disorders of the eye

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MARCHIONNI M.A. ET AL.: "Neuregulins as potential drugs for neurological disorders.", COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY., vol. 61, 1996, pages 459 - 472, XP009007573 *
See also references of WO9918976A1 *

Also Published As

Publication number Publication date
AU9604298A (en) 1999-05-03
CA2306228A1 (en) 1999-04-22
JP2001519400A (en) 2001-10-23
AU745324B2 (en) 2002-03-21
KR20010031103A (en) 2001-04-16
EP1028735A1 (en) 2000-08-23
WO1999018976A1 (en) 1999-04-22

Similar Documents

Publication Publication Date Title
EP1028735A4 (en) Therapeutic methods comprising use of a neuregulin
SI0979269T1 (en) Use of a fermenter
ZA982368B (en) New therapeutic combinations
HU9700071D0 (en) Use of muramilpeptides
GB9719161D0 (en) New therapeutic method
GB9620777D0 (en) Therapeutic use
GB9723999D0 (en) Therapeutic use
IL130209A (en) Therapeutic application of a thienylcylohexylamine derivatives
GB9726701D0 (en) Therapeutic use
GB2294532B (en) Use of a Crucible
GB9726702D0 (en) Therapeutic use
TW328219U (en) Structure of a chair-ladder
GB9708288D0 (en) Therapeutic use
GB9726699D0 (en) Therapeutic use
GB9721195D0 (en) Therapeutic use
GB9721220D0 (en) Therapeutic use
GB9721221D0 (en) Therapeutic use
GB9721265D0 (en) Therapeutic use
GB9721193D0 (en) Therapeutic use
GB9717260D0 (en) Therapeutic use
GB9708289D0 (en) Therapeutic use
GB9721192D0 (en) Therapeutic use
GB9721191D0 (en) Therapeutic use
GB9721266D0 (en) Therapeutic use
GB9721190D0 (en) Therapeutic use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000504

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CENES PHARMACEUTICALS INC.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CENES PHARMACEUTICALS, INC.

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 48/00 B

Ipc: 7C 07K 14/475 B

Ipc: 7A 61K 38/18 A

Ipc: 7A 61P 25/00 B

A4 Supplementary search report drawn up and despatched

Effective date: 20030623

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050503